Literature DB >> 12815474

Early lymphocyte recovery is an important determinant of outcome following allogeneic transplantation with CD34+ selected graft and limited T-cell addback.

S Chakrabarti1, J Brown, M Guttridge, D H Pamphilon, A Lankester, D I Marks.   

Abstract

We evaluated the outcome of 29 patients (age 22-60 years), who received a CD34+selected related (n=16) or unrelated graft (n=13) with limited T-cell addback (TCAB) (median 5.9 x 10(4)/kg) following full-intensity conditioning for haematological malignancies. In all, 16 patients (55%) had either advanced disease or previous transplants. The cumulative incidences of grade 2-4 acute GVHD were 15.4 and 19.2% and that for chronic extensive GVHD were 35 and 37% in related and unrelated graft recipients, respectively. The strongest predictor of nonrelapse mortality and overall survival was the absolute lymphocyte count (ALC) at 30 days; patients with ALC<0.35 x 10(9)/l having an NRM and OS of 59.2 and 24.7%, compared to 10 and 90% in those with a higher ALC. Patients with acute leukaemia had poorer survival and this was associated with a lower ALC as well. Thus, TCAB with a CD34+ selected graft resulted in a comparable outcome in both older and younger patients, but the survival was strongly influenced by early lymphocyte recovery.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12815474     DOI: 10.1038/sj.bmt.1704082

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  14 in total

1.  Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation.

Authors:  Bipin N Savani; Stephan Mielke; Katayoun Rezvani; Aldemar Montero; Agnes S Yong; Laura Wish; Jeannine Superata; Roger Kurlander; Anurag Singh; Richard Childs; A John Barrett
Journal:  Biol Blood Marrow Transplant       Date:  2007-08-24       Impact factor: 5.742

2.  Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplant.

Authors:  Jenna D Goldberg; Junting Zheng; Ravin Ratan; Trudy N Small; Kuan-Chi Lai; Farid Boulad; Hugo Castro-Malaspina; Sergio A Giralt; Ann A Jakubowski; Nancy A Kernan; Richard J O'Reilly; Esperanza B Papadopoulos; James W Young; Marcel R M van den Brink; Glenn Heller; Miguel-Angel Perales
Journal:  Leuk Lymphoma       Date:  2017-01-10

Review 3.  Selected biological issues affecting relapse after stem cell transplantation: role of T-cell impairment, NK cells and intrinsic tumor resistance.

Authors:  Marcel van den Brink; Markus Uhrberg; Lorenz Jahn; John F DiPersio; Michael A Pulsipher
Journal:  Bone Marrow Transplant       Date:  2018-01-24       Impact factor: 5.483

4.  Immune recovery after allogeneic hematopoietic stem cell transplantation: is it time to revisit how patients are monitored?

Authors:  Miguel-Angel Perales; Marcel R M van den Brink
Journal:  Biol Blood Marrow Transplant       Date:  2012-09-27       Impact factor: 5.742

5.  Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia.

Authors:  Bipin N Savani; Katayoun Rezvani; Stephan Mielke; Aldemar Montero; Roger Kurlander; Charles S Carter; Susan Leitman; Elizabeth J Read; Richard Childs; A John Barrett
Journal:  Blood       Date:  2005-08-30       Impact factor: 22.113

6.  Lymphocyte recovery is a major determinant of outcome after matched unrelated myeloablative transplantation for myelogenous malignancies.

Authors:  Katarina Le Blanc; A John Barrett; Marie Schaffer; Hans Hägglund; Per Ljungman; Olle Ringdén; Mats Remberger
Journal:  Biol Blood Marrow Transplant       Date:  2009-09       Impact factor: 5.742

7.  Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration.

Authors:  Jeannine S McCune; Paolo Vicini; David H Salinger; Paul V O'Donnell; Brenda M Sandmaier; Claudio Anasetti; Donald E Mager
Journal:  Cancer Chemother Pharmacol       Date:  2014-11-06       Impact factor: 3.333

8.  Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML.

Authors:  R M Saliba; K V Komanduri; S Giralt; J de Souza; P Patah; B Oran; D Couriel; G Rondon; R E Champlin; M de Lima
Journal:  Bone Marrow Transplant       Date:  2008-11-17       Impact factor: 5.483

9.  Comparison of reference values for immune recovery between event-free patients receiving haploidentical allografts and those receiving human leukocyte antigen-matched sibling donor allografts.

Authors:  Xuying Pei; Xiangyu Zhao; Yu Wang; Lanping Xu; Xiaohui Zhang; Kaiyan Liu; Yingjun Chang; Xiaojun Huang
Journal:  Front Med       Date:  2017-09-08       Impact factor: 4.592

10.  Optimal Threshold and Time of Absolute Lymphocyte Count Assessment for Outcome Prediction after Bone Marrow Transplantation.

Authors:  Ulas D Bayraktar; Denái R Milton; Michele Guindani; Gabriela Rondon; Julianne Chen; Gheath Al-Atrash; Katayoun Rezvani; Richard Champlin; Stefan O Ciurea
Journal:  Biol Blood Marrow Transplant       Date:  2015-10-31       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.